• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Vincerx Pharma Inc.

    11/14/24 3:39:40 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VINC alert in real time by email
    SC 13G 1 armistice-vinc093024.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    Vincerx Pharma, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    92731L106

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  92731L106
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,993,104
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,993,104
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,993,104
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  92731L106
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,993,104
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,993,104
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,993,104
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 92731L106
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Vincerx Pharma, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    260 Sheridan Avenue, Suite 400

    Palo Alto, California 94306

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, $0.0001 par value per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    92731L106

     

    CUSIP No.  92731L106
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 92731L106
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of September 30, 2024:

    Armistice Capital, LLC - 2,993,104

    Steven Boyd - 2,993,104  

    (b) Percent of Class as of September 30, 2024:

    Armistice Capital, LLC - 9.99%

    Steven Boyd - 9.99% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 2,993,104

    Steven Boyd - 2,993,104 

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 2,993,104

    Steven Boyd - 2,993,104

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 92731L106
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 92731L106
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $VINC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VINC

    DatePrice TargetRatingAnalyst
    1/14/2022$25.00Buy
    HC Wainwright & Co.
    12/23/2021$25.00Overweight
    Cantor Fitzgerald
    11/1/2021$24.00Outperform
    SVB Leerink
    9/13/2021$30.00Buy
    Laidlaw
    8/25/2021$26.00Buy
    B. Riley Securities
    8/13/2021$33.00 → $30.00Buy
    Chardan Capital
    More analyst ratings

    $VINC
    SEC Filings

    See more
    • SEC Form EFFECT filed by Vincerx Pharma Inc.

      EFFECT - Vincerx Pharma, Inc. (0001796129) (Filer)

      5/5/25 12:15:04 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Vincerx Pharma Inc.

      EFFECT - Vincerx Pharma, Inc. (0001796129) (Filer)

      5/5/25 12:15:05 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Vincerx Pharma Inc.

      EFFECT - Vincerx Pharma, Inc. (0001796129) (Filer)

      5/5/25 12:15:15 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VINC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

      Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025 Trading to be permanently suspended by Nasdaq at the open of business on April 23, 2025 SAN MATEO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission ("SEC") on or about April 28, 2025, which will remove Vincerx's common stock from listing and registration on The Nasdaq Stock Market ("Nasdaq"). On April 14, 2025, Vincerx received written notice from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because

      4/17/25 4:45:00 PM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

      SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI, regarding a potential merger. Following this decision, the Company's board of directors has authorized management to initiate wind-down activities and continue exploring monetization of assets and out-licensing opportunities. "I want to express our deepest gratitude to the investigators, patients, employees, and partners who have supported Vincerx's mission," said Raquel Izumi, Ph.D., Acting Chief Executive Officer of Vincerx. "Your co

      4/8/25 4:05:00 PM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

      SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that it has entered into a non-binding letter of intent ("LOI") with Global Digital Holdings Inc., conducting business as QumulusAI, a privately-held, high-performance computing infrastructure company for artificial intelligence (AI), relating to a business combination between Vincerx and QumulusAI. The contemplated transaction would result in QumulusAI becoming a publicly traded company through a reverse triangular merger with Vincerx. Under the proposed terms, a subsidiary of Vincerx would merge into QumulusAI, with QumulusAI stockholders receiving shares of Vincerx common stock.

      3/18/25 8:52:56 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VINC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Vincerx Pharma Inc.

      SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)

      11/14/24 3:39:40 PM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vincerx Pharma Inc.

      SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

      11/14/24 11:57:03 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vincerx Pharma Inc.

      SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

      11/13/24 8:32:26 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VINC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Haas Kevin claimed ownership of 42,776 shares (SEC Form 3)

      3 - Vincerx Pharma, Inc. (0001796129) (Issuer)

      1/6/25 4:29:47 PM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Thomas Tom C

      4 - Vincerx Pharma, Inc. (0001796129) (Issuer)

      8/14/24 8:11:28 PM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Hamdy Ahmed Md

      4 - Vincerx Pharma, Inc. (0001796129) (Issuer)

      8/14/24 8:07:30 PM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VINC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Vincerx Pharma with a new price target

      HC Wainwright & Co. initiated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $25.00

      1/14/22 6:06:29 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Vincerx Pharma with a new price target

      Cantor Fitzgerald initiated coverage of Vincerx Pharma with a rating of Overweight and set a new price target of $25.00

      12/23/21 6:37:41 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on Vincerx Pharma with a new price target

      SVB Leerink initiated coverage of Vincerx Pharma with a rating of Outperform and set a new price target of $24.00

      11/1/21 6:31:16 AM ET
      $VINC
      Biotechnology: Pharmaceutical Preparations
      Health Care